Cisen Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Cisen Pharmaceutical Co., Ltd. carries a market capitalization of 6.32B, placing it among publicly traded companies globally. Its enterprise value stands at 3.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.32B |
| Enterprise Value | 3.70B |
Share Statistics
Cisen Pharmaceutical Co., Ltd. currently has 452.75M shares outstanding.
| Shares Outstanding | 452.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Cisen Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 13.45. The price-to-sales ratio is 1.72, and the price-to-book ratio stands at 1.60.
| PE Ratio | 13.45 |
| PS Ratio | 1.72 |
| PB Ratio | 1.60 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | 64.49 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Cisen Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 7.83 and an EV/FCF ratio of 36.35. The EV/Sales ratio of 1.01 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.83 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.01 |
| EV / EBITDA | 7.83 |
| EV / EBIT | 7.83 |
| EV / FCF | 36.35 |
Financial Position
Cisen Pharmaceutical Co., Ltd. maintains a current ratio of 3.65, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.68, indicating moderate leverage, while an interest coverage ratio of 96.42 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.65 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 0.09 |
| Interest Coverage | 96.42 |
Financial Efficiency
Cisen Pharmaceutical Co., Ltd. posts a return on equity of 12.34 and a return on invested capital of 6.81.
| Return on Equity (ROE) | 12.34 |
| Return on Assets (ROA) | 6.27 |
| Return on Invested Capital (ROIC) | 6.81 |
| Return on Capital Employed (ROCE) | 11.97 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.06 |
Taxes
Over the trailing twelve months, Cisen Pharmaceutical Co., Ltd. has paid 67.65M in income taxes, reflecting an effective tax rate of 12.52.
| Income Tax | 67.65M |
| Effective Tax Rate | 12.52 |
Stock Price Statistics
Cisen Pharmaceutical Co., Ltd.'s stock has declined approximately -9.63777% over the past 52 weeks. The 50-day moving average sits at 14.20, while the 200-day moving average is 17.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.63777% |
| 50-Day Moving Average | 14.20 |
| 200-Day Moving Average | 17.35 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cisen Pharmaceutical Co., Ltd. generated 3.65B in revenue and converted that into 467.74M in net income, yielding earnings per share of 1.05. EBITDA reached 472.70M, while operating income came in at 472.70M.
| Revenue | 3.65B |
| Gross Profit | 2.03B |
| Operating Income | 472.70M |
| Pretax Income | 540.16M |
| Net Income | 467.74M |
| EBITDA | 472.70M |
| EBIT | 472.70M |
| Earnings Per Share (EPS) | 1.05 |
Balance Sheet
Cisen Pharmaceutical Co., Ltd. holds 2.67B in cash and equivalents against 41.35M in total debt, resulting in a net debt position of -638.83M. Total book value stands at 3.93B, with working capital of 3.70B providing operational flexibility.
| Cash & Cash Equivalents | 2.67B |
| Total Debt | 41.35M |
| Net Debt | -638.83M |
| Equity (Book Value) | 3.93B |
| Book Value Per Share | 8.75 |
| Working Capital | 3.70B |
Cash Flow
After subtracting -97.52M in capital expenditures, free cash flow totaled -97.52M - equivalent to -0.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -97.52M |
| Free Cash Flow | -97.52M |
| FCF Per Share | -0.22 |
Margins
Cisen Pharmaceutical Co., Ltd. operates with a gross margin of 55.71, reflecting its pricing power and cost economics. The operating margin of 12.95 and net profit margin of 12.81 provide insight into operational efficiency.
| Gross Margin | 55.71 |
| Operating Margin | 12.95 |
| Pretax Margin | 14.80 |
| Profit Margin | 12.81 |
| EBITDA Margin | 12.95 |
Dividends & Yields
The company's payout ratio of 42.95 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.46 |
| Dividend Yield | N/A |
| Payout Ratio | 42.95 |
| Shareholder Yield | 3.95 |
| FCF Yield | 1.55 |
Scores
Cisen Pharmaceutical Co., Ltd. posts an Altman Z-Score of 4.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.48 |